INHIBIKASE THERAPEUTICS, INC. (IKT) Capital expenditures 2021–2025
INHIBIKASE THERAPEUTICS, INC. (IKT) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.
$13,399FY2025 · since FY2021: $0 → $13,399
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $13,399 | — |
| FY2024 | $0 | -100.0% |
| FY2023 | $14,238 | -94.1% |
| FY2022 | $243,255 | — |
| FY2021 | $0 | — |
Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.
Source: SEC XBRL filings · For reference only · Not investment advice